Director, Informatics and Technology MOMA Therapeutics, Massachusetts, United States
Conversations about data are ubiquitous across the biotech and pharmaceutical industries, but so many organizations still miss the mark on the strategy and execution of digitized research and analytics. Technology and data science leaders in the startup space have a rare and short-lived opportunity to create a framework from the beginning that can set their companies apart and create value for the rest of the organization. The speed of innovation, research, and the scale of competition across the industry has positioned the use of data as a huge differentiator in successful outcomes.
This presentation will focus on how to create an executable digital data strategy, and perhaps more importantly, why it must be justified and bought into by the rest of the early team - both in leadership all the way through to bench scientists. Data is a core asset and while the typical FAIR principals still apply, setting up an ELN and calling it a day won't provide the deep insights and transformative knowledge that accelerates drug discovery and research. A long-term strategy with built-in adaptability will allow a startup biotech to surface knowledge from data at an exponential rate, and will pay dividends in research speed, operations, and in the avoidance of costly data transformation projects in the future. Well-organized data and a culture of citizen data analysts within the research team can open the doors for your data to set you apart among the crowded biotech industry.
